Combination therapy in exudative age-related macular degeneration: Visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab

Canadian Journal of Ophthalmology

Volumn 45, Issue 4, 2010, Pages 375-380

  Wan, Michael J ^a   Hooper, Phil L ^a   Sheidow, Tom G ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Age related maculopathy; Bevacizumab; Photodynamic therapy; Verteporfin

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HYPERTENSION ENCEPHALOPATHY; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; THROMBOEMBOLISM; UVEITIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; EXUDATE; INJECTION; MACULAR DEGENERATION; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; VITREOUS BODY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77955463326     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-011     Document Type: Article

References (24)

1. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4.
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
3. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
4. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. NEngl J Med 2004;351:2805-16.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
9. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46.
10. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
11. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-8.
12. Kaiser PK. Verteporfin photodynamic therapy and antiangiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007;23:477-87.
13. Aggio FB, Melo GB, Höfling-Lima AL, Eid Farah M. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmol Scand 2006;84:831-3.
14. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-relatedmacular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273-80.
15. Lazić R, Gabrić N, Dekaris I, Gavrić M, Bosnar D. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol 2007;31 Suppl 1:71-5.
16. Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246:17-25.
17. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-93.
18. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85.
19. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 2007;27:3465-70.
20. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecanand bevacizumab-based therapy. J Clin Oncol 2005;23:2574-6.
21. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112:500-9.
22. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
23. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-16.
24. Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol 2007;21:185-7.